Navigation Links
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Date:1/11/2010

op15='81131652';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.peregrineinc.com/">www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended October 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release


    Contacts:
    GendeLLindheim BioCom Partners
    Investors       
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
2. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
3. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
8. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
9. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
10. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
11. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... According to a new market research report, ... , published by Mordor Intelligence, the Global market is expected ... 2020, with North America being the ... global market size. The Global market for Stem Cells is ... period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... BIRMINGHAM, Ala., July 29, 2015 /PRNewswire/ ... the nation,s largest providers of post-acute healthcare services, ... reported its results of operations for the second ... second quarter was characterized by strong volume growth ... our Adjusted EBITDA," said Jay Grinney, President and ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... Management to discuss positive corporate developments and ... call, SANTA CLARA, Calif., Oct. 14 ... cardiac diagnostic and services company, today,announced that ... discuss,recent corporate developments and provide an update ...
... release date, NATICK, Mass., Oct. 14 ... the following comments reinforcing,the strength of its balance ... and the Company,s stock price,volatility have had no ... performance of the Company. Strong cash flow generation,during ...
... China, Oct. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced preliminary selected,unaudited financial ... 30, 2008,and updated its guidance for the ...
Cached Biology Technology:NewCardio Management to Host Conference Call on October 21 2NewCardio Management to Host Conference Call on October 21 3Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 2Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 2WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 4WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 5WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 6WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 7WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 8
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... New combinations of agents based on the oldest synthetic ... spread of malaria parasites and make a significant contribution ... "Roll Back Malaria Initiative." In a study on 160 ... medicine from the Heidelberg University Hospital have shown that ...
... Wash. -- Some researchers hope to turn plants into ... this, scientists have to learn how to convert plant ... cheaply and efficiently. In new research, chemists have successfully ... directly into the building block called HMF in one ...
... Individuals with heart disease are twice as likely to ... the medical community has largely been unable to explain. ... Hospital, in conjunction with The Montral Heart Institute, University ... genetic variations that contribute to depression in heart disease ...
Cached Biology News:Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2Genetic factors may predict depression in heart disease patients 2Genetic factors may predict depression in heart disease patients 3
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Mouse monoclonal [88B] to nicotinic Acetylcholine Receptor ( Abpromise for all tested applications)....
D4-GDI rabbit polyclonal antibody...
Biology Products: